论文部分内容阅读
Sunitinib is considered as the standard treatment for metastatic clear cell renal cell carcinoma (ccRCC).However, most tumors eventually develop resistance to sunitinib, and genetic alterations acquiring resistance require further investigations.In this study, we aim to elucidate potential resistance mechanisms in ccRCC in vivo model by exome sequencing.We have generated several cohort of patient-derived primary xenograft model, and one of which develops complete resistance to sunitinib with continuous drug exposure.DNA from resistant tumors, control tumors and clinical sample were extracted.We performed whole exome sequencing using Illumina Hiseq 2000.Non-synonymous single nucleotide variants (SNVs) were filtered to identify those with at least identical non-reference genotypes from at least total reads.Comparison of resistant and control data identified common SNVs among resistant tumor that were absent in control tumor.Further studies to explore whether these variants arise in ccRCC are expected to reveal the clinical relevance of genetic alterations identified in this model system.